Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates

BioDrugs

Volumn 28, Issue 4, 2014, Pages 383-391

  Sauerborn, Melody ^a   Van Dongen, William ^a  

^a TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; BRENTUXIMAB VEDOTIN; CETUXIMAB; CYTOTOXIC AGENT; HUMAN GROWTH HORMONE; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

ANALYTIC METHOD; ANTIBODY DETECTION; BIOASSAY; CANCER CHEMOTHERAPY; DRUG APPROVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE SYSTEM; IMMUNOASSAY; IMMUNOGENICITY; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR BINDING ASSAY; REVIEW; RISK ASSESSMENT; ANIMAL; DRUG DESIGN; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; MASS SPECTROMETRY; NEOPLASMS;

EID: 84904855143     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-014-0096-z     Document Type: Review

References (47)

1. Flygare JA, Pillow TH, Aristoff P. Antibody - drug conjugates for the treatment of cancer. Chem Biol Drug Des. 2013;81(1):113-21.
2. Iyer U, Kadambi VJ. Antibody drug conjugates - Trojan horses in the war on cancer. J Pharmacol Toxicol Methods. 2011;64(3):207-12.
3. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol. 2013;76(2):248-62.
4. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631-7.
5. Lewis Phillips GD, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280-90.
6. Hamblett KJ, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063-70. (Pubitemid 39383058)
7. Xu K, et al. Characterization of intact antibody - drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem. 2011;412(1):56-66.
8. Sun X, et al. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem. 2011;22(4):728-35.
9. Gorovits B, et al. Bioanalysis of antibody - drug conjugates: American Association of Pharmaceutical Scientists Antibody - Drug Conjugate Working Group position paper. Bioanalysis. 2013;5(9):997-1006.
10. Hopfgartner G, Bourgogne E. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. Mass Spectrom Rev. 2003;22(3):195-214.
11. Xu RN, et al. Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. J Pharm Biomed Anal. 2007;44(2):342-55. (Pubitemid 46880094)
12. Stephan JP, Kozak KR, Wong WL. Challenges in developing bioanalytical assays for characterization of antibody - drug conjugates. Bioanalysis. 2011;3(6):677-700.
13. Sanderson RJ, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11(2 Pt 1):843-52. (Pubitemid 40116913)
14. Stephan JP, et al. Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem. 2008;19(8):1673-83.
15. Wakankar A, et al. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs. 2011;3(2):161-72.
16. Kozak KR, et al. Total antibody quantification for MMAE-conjugated antibody - drug conjugates: impact of assay format and reagents. Bioconjug Chem. 2013;24(5):772-9.
17. Li H, et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal Chem. 2012;84(3):1267-73.
18. van den Broek I, Niessen WM, van Dongen WD. Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;929:161-79.
19. Fernandez Ocana M, et al. Clinical pharmacokinetic assessment of an anti-MAdCAM monoclonal antibody therapeutic by LC-MS/MS. Anal Chem. 2012;84(14):5959-67.
20. Kaur S, et al. Bioanalytical assay strategies for the development of antibody - drug conjugate biotherapeutics. Bioanalysis. 2013;5(2):201-26.
21. Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res. 2012;29(9):2354-66.
22. Rispens T, et al. Mechanism of immunoglobulin G4 Fab-arm exchange. J Am Chem Soc. 2011;133(26):10302-11.
23. Labrijn AF, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27(8):767-71.
24. Stubenrauch K, et al. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab Dispos. 2010;38(1):84-91.
25. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994;38(8):1695-702. (Pubitemid 24250712)
26. Baker MP, et al. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself. 2010;1(4):314-22.
27. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20(Suppl 6):vi3-9.
28. Reichert JM. Antibodies to watch in 2014. MAbs 2013;6(1):5-14.
29. Hansel TT, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325-38.
30. Chung CH, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(11):1109-17. (Pubitemid 351398485)
31. Ghaderi D, et al. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev. 2012;28:147-75.
32. Yin BJ, et al. Generation of glyco-engineered BY2 cell lines with decreased expression of plant-specific glycoepitopes. Protein Cell. 2011;2(1):41-7.
33. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab. 1980;51(4):691-7. (Pubitemid 10024715)
34. Sauerborn M, et al. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci. 2010;31(2):53-9.
35. Ratanji KD, et al. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 2014;11(2):99-109.
36. Vugmeyster Y, et al. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem. 2012;3(4):73-92.
37. Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012;24(3):306-11.
38. Shin SK, et al. Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin. Int Immunopharmacol. 2011;11(12):2237-41.
39. Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost. 2013;11(Suppl 1):84-98.
40. Finco D, et al. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J Pharm Biomed Anal. 2011;54(2):351-8.
41. Buttel IC, et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals. 2011;39(2):100-9.
42. Jawa V, et al. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol. 2013;149(3):534-55.
43. Hollander I, Kunz A, Hamann PR. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug Chem. 2008;19(1):358-61. (Pubitemid 351213870)
44. Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother. 2013;62(2):217-23.
45. Hoofring SA, et al. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. Bioanalysis. 2013;5(9):1041-55.
46. Koren E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333(1-2):1-9.
47. Barbosa MD, et al. Addressing drug effects on cut point determination for an anti-drug antibody assay. J Immunol Methods. 2012;384(1-2):152-6.